MCA205 cancers treated with (R)-crizotinib, alone or together with CDDP, exhibited a significant increase (p < 0.001, ANOVA test) in the local presence of activated dendritic cells (DC) expressing CD11c and CD86 (Supplementary Fig. 9a, d), CTL (Supplementary Fig. 9b, e). The gene discussed is CD86; the disease is cancer.